RT Journal Article
T1 Drug resistance mutations in HIV-2 patients failing raltegravir and influence on dolutegravir response.
A1 Requena, Silvia
A1 Treviño, Ana
A1 Cabezas, Teresa
A1 Garcia-Delgado, Rosa
A1 Amengual, María José
A1 Lozano, Ana Belén
A1 Peñaranda, María
A1 Fernández, Juan Manuel
A1 Soriano, Vicente
A1 de Mendoza, Carmen
A1 Spanish HIV-2 Study Group, 
AB A broader extent of amino acid substitutions in the integrase of HIV-2 compared with HIV-1 might enable greater cross-resistance between raltegravir and dolutegravir in HIV-2 infection. Few studies have examined the virological response to dolutegravir in HIV-2 patients that failed raltegravir. All patients recorded in the HIV-2 Spanish cohort were examined. The integrase coding region was sequenced in viraemic patients. Changes associated with resistance to raltegravir and dolutegravir in HIV-1 were recorded. From 319 HIV-2-infected patients recorded in the HIV-2 Spanish cohort, 53 integrase sequences from 30 individuals were obtained (20 raltegravir naive and 10 raltegravir experienced). Only one secondary mutation (E138A) was found in one of the 20 raltegravir-naive HIV-2 patients. For raltegravir-experienced individuals, the resistance mutation profile in 9 of 10 viraemic patients was as follows: N155H + A153G/S (four); Y143G + A153S (two); Q148R + G140A/S (two); and Y143C + Q91R (one). Of note, all patients with Y143G and N155H developed a rare non-polymorphic mutation at codon 153. Rescue therapy with dolutegravir was given to 5 of these 10 patients. After >6 months on dolutegravir therapy, three patients with baseline N155H experienced viral rebound. In two of them N155H was replaced by Q148K/R and in another by G118R. A wide repertoire of resistance mutations in the integrase gene occur in HIV-2-infected patients failing on raltegravir. Although dolutegravir may allow successful rescue in most HIV-2 raltegravir failures, we report and characterize three cases of dolutegravir resistance in HIV-2 patients, emerging variants Q148K and Q148R and a novel change G118R.
YR 2017
FD 2017
LK http://hdl.handle.net/10668/11042
UL http://hdl.handle.net/10668/11042
LA en
DS RISalud
RD Apr 13, 2025